Question 1

What is a GLP-1 receptor agonist?

Accepted Answer

A GLP-1 receptor agonist (GLP-1 RA) is a prescription medicine that mimics the gut hormone GLP-1. It helps your pancreas release insulin when blood sugar is high, reduces appetite, and slows stomach emptying. In India, this drug class includes semaglutide, liraglutide, dulaglutide, and the dual GIP/GLP-1 agent tirzepatide. These are not brand names alone—they are distinct molecules your doctor selects based on your health profile. Kesho explains how they work; we do not prescribe or sell them.

Question 2

How is GLP-1 different from insulin?

Accepted Answer

Insulin directly lowers blood sugar by replacing or supplementing the hormone your pancreas makes. GLP-1 receptor agonists stimulate your own insulin release in a glucose-dependent way—meaning less hypoglycaemia risk when used alone. GLP-1 medicines also reduce appetite and slow digestion, effects insulin does not provide. Some type 2 diabetes patients use both under careful medical supervision, with doses adjusted to prevent low blood sugar.

Question 3

How long before GLP-1 shows results?

Accepted Answer

Blood sugar improvements often appear within four to eight weeks as doses are titrated upward. Weight changes typically become noticeable after eight to twelve weeks. Maximum benefits may require three to six months of consistent use alongside nutrition and physical activity. Early weeks may bring nausea before appetite reduction fully develops—patience during titration is important.

Question 4

Is GLP-1 approved for use in India?

Accepted Answer

Yes. CDSCO has approved GLP-1 receptor agonists including semaglutide and tirzepatide for specified indications such as type 2 diabetes and chronic weight management. Medicines must be purchased from licensed pharmacies with a valid prescription. Unapproved imports and compounded products are not equivalent to CDSCO-regulated medicines.

Question 5

Which GLP-1 drug classes are CDSCO-approved in India?

Accepted Answer

As of 2026, CDSCO has approved medicines in the GLP-1 receptor agonist class—including semaglutide, liraglutide, and dulaglutide—as well as the dual GIP/GLP-1 receptor agonist tirzepatide, for specified indications such as type 2 diabetes and chronic weight management. Each molecule has distinct approved formulations (injectable pens, some oral). Approval status applies to licensed manufacturers' products sold through pharmacies with valid prescriptions—not to compounded, imported, or unregistered preparations.

Question 6

Is semaglutide safe to use in India?

Accepted Answer

CDSCO-approved semaglutide from licensed pharmacies is considered safe for appropriate patients when prescribed and monitored by a qualified physician. Safety depends on correct indication, dose titration, and screening for contraindications such as MEN2 or medullary thyroid carcinoma family history. Products from unverified online sellers, without cold-chain handling, or without prescription carry additional risks unrelated to the molecule itself. Report persistent nausea, severe abdominal pain, or neck symptoms promptly.

Question 7

What BMI is needed for GLP-1 in India?

Accepted Answer

For obesity pharmacotherapy, ICMR and RSSDI-aligned practice often considers BMI ≥27.5 kg/m² without comorbidities, or BMI ≥25 kg/m² with comorbidities such as prediabetes, hypertension, dyslipidaemia, fatty liver, or sleep apnoea—after structured lifestyle intervention. For type 2 diabetes, BMI alone is not the deciding factor; inadequate glycaemic control despite metformin and lifestyle is key. South Asian thin-fat phenotype means waist circumference and metabolic risk matter alongside scale weight.

Question 8

Can I get GLP-1 with only prediabetes?

Accepted Answer

Prediabetes alone rarely triggers GLP-1 prescribing, but prediabetes as a comorbidity may support obesity pharmacotherapy when BMI criteria are met and lifestyle alone has not succeeded. Metformin and intensive lifestyle remain more established for diabetes prevention. Your endocrinologist, internal medicine specialist, or cardiologist individualises this decision.

Question 9

Who should not take GLP-1 medicines?

Accepted Answer

Contraindications include pregnancy and breastfeeding; personal or family history of medullary thyroid carcinoma or MEN2; history of severe pancreatitis; and type 1 diabetes (not indicated). Caution applies in severe gastroparesis, active eating disorders without psychiatric support, and frail patients where further weight loss is harmful. Full medical history screening precedes any prescription.

Question 10

Do I need a specialist or can my GP prescribe?

Accepted Answer

Endocrinologists, internal medicine specialists, and cardiologists commonly initiate and monitor GLP-1 therapy in India—especially for complex obesity, insulin combinations, cardiovascular disease, or thyroid history. General physicians may co-manage stable patients after specialist initiation. Tier-2 city patients may use teleconsultation with metro specialists plus local follow-up. Ensure your prescriber is NMC-registered.

Question 11

Can I take GLP-1 without having diabetes?

Accepted Answer

Yes, for eligible patients. CDSCO has approved certain GLP-1 receptor agonists for chronic weight management in adults meeting BMI and comorbidity criteria—even without type 2 diabetes. This is distinct from off-label use. You still need a prescription, medical screening, and structured lifestyle support. GLP-1 is not a cosmetic weight-loss shortcut for people below guideline thresholds.

Question 12

Is GLP-1 suitable for elderly patients in India?

Accepted Answer

GLP-1 can benefit older adults with type 2 diabetes or obesity-related comorbidities, but frail patients, those with unintentional weight loss, or adults over 75 need careful assessment. Risks include nausea affecting nutrition, muscle loss without adequate protein, and falls if dehydration occurs. Start low, titrate slowly, and monitor kidney function, bone health, and functional status. Family involvement in injection technique and storage helps.

Question 13

Can women with PCOS use GLP-1 in India?

Accepted Answer

PCOS with insulin resistance and obesity may make a patient eligible for GLP-1 when BMI criteria are met and lifestyle intervention has not achieved goals. GLP-1 may improve weight, metabolic markers, and in some cases menstrual regularity—but it is not a fertility treatment. Stop before planned conception with medical guidance. Combine with nutrition, activity, and gynaecology or endocrinology follow-up.

Question 14

How much does GLP-1 cost per month in India?

Accepted Answer

Out-of-pocket costs in 2026 typically range from approximately ₹8,000 to ₹25,000 monthly depending on molecule (semaglutide vs tirzepatide), dose, brand versus generic, and city. Generic semaglutide may reduce costs to roughly ₹6,000–₹14,000. Oral semaglutide is often similarly priced to injections. Budget for long-term therapy—stopping due to cost without medical planning often leads to regain.

Question 15

Does health insurance cover GLP-1 in India?

Accepted Answer

Most standard policies do not cover outpatient GLP-1 for obesity. Some corporate health plans partially cover diabetes indications after prior authorisation and documented HbA1c failure on metformin. CGHS and PM-JAY generally do not include routine outpatient GLP-1. Ask your HR benefits team and read OPD pharmacy riders carefully.

Question 16

Are generic semaglutide products safe?

Accepted Answer

CDSCO-approved generic semaglutide from licensed manufacturers must meet bioequivalence standards—distinct from illegal imports or social-media sellers. Verify manufacturer name, batch number, expiry, and cold-chain handling. Extremely low prices from unverified sources are red flags for counterfeit products.

Question 17

Can I buy GLP-1 without a prescription?

Accepted Answer

No. GLP-1 RAs are Schedule H prescription-only medicines in India. Purchasing without prescription is illegal and exposes you to counterfeit, degraded, or incorrectly dosed products. CDSCO has issued advisories against unapproved online sellers.

Question 18

Which GLP-1 drug class is the most affordable in India?

Accepted Answer

Among CDSCO-approved options, generic injectable semaglutide and older molecules such as liraglutide or dulaglutide typically sit at the lower end of monthly out-of-pocket costs—roughly ₹6,000–₹14,000 for semaglutide generics versus ₹15,000–₹25,000 for newer dual-agonist therapy at studied doses. Oral semaglutide is often similarly priced to injections. Actual cost depends on dose, pharmacy, and city—not on social media claims. Discuss molecule choice with your doctor based on clinical need and sustainable budget.

Question 19

How much does GLP-1 cost in Mumbai, Delhi, or Bangalore?

Accepted Answer

Metro pharmacy pricing in 2026 is broadly similar across Mumbai, Delhi NCR, and Bangalore for the same molecule and dose—typically ₹8,000–₹25,000 monthly out of pocket, with generic semaglutide toward the lower range. Marginal differences reflect pharmacy markups, corporate hospital OPD dispensing fees, and cold-chain logistics—not fundamentally different drug pricing by city. Tier-2 cities may see slightly higher per-unit costs due to limited stockist networks. Always compare licensed pharmacies and budget for long-term therapy.

Question 20

Is compounded or custom-mixed semaglutide legal in India?

Accepted Answer

No. CDSCO regulates finished pharmaceutical products from licensed manufacturers—not pharmacy-compounded GLP-1 preparations for individual patients. Compounded semaglutide promoted on social media falls outside approved quality, dosing, and cold-chain standards. CDSCO advisories warn against unapproved GLP-1 products. Use only CDSCO-approved medicines from licensed pharmacies with a valid prescription.

Question 21

What are the most common GLP-1 side effects?

Accepted Answer

Nausea is most frequent, followed by vomiting, diarrhoea, constipation, bloating, and reflux—especially during the first four to eight weeks of each dose increase. Eating smaller portions, avoiding greasy foods, and following gradual titration schedules reduce symptoms. Most patients improve as the body adapts. Persistent vomiting causing dehydration requires urgent medical care.

Question 22

Does GLP-1 cause thyroid cancer?

Accepted Answer

Rodent studies prompted regulatory precautions, but definitive human causation in patients without medullary thyroid carcinoma or MEN2 family history is not established. GLP-1 is contraindicated with personal or family MTC/MEN2 history. Report neck lumps, hoarseness, or swallowing difficulty to your doctor.

Question 23

What are signs of pancreatitis on GLP-1?

Accepted Answer

Seek emergency care for severe upper abdominal pain lasting hours, often radiating to the back, with persistent vomiting and inability to tolerate fluids. Stop the medicine and contact your doctor immediately if these symptoms occur.

Question 24

Can GLP-1 affect kidney function?

Accepted Answer

GLP-1 RAs may slow diabetic kidney disease progression in trials. However, dehydration from vomiting during titration can temporarily raise creatinine. Stay hydrated, especially in Indian summers. Many products need no dose change until advanced chronic kidney disease—specialist guidance required.

Question 25

Is GLP-1 safe during pregnancy?

Accepted Answer

No. GLP-1 receptor agonists are not recommended during pregnancy or breastfeeding due to limited human safety data. Stop before conception with medical guidance—semaglutide's long half-life may require washout weeks. Use pregnancy-safe diabetes treatments such as insulin if needed.

Question 26

Can GLP-1 cause hair loss?

Accepted Answer

Hair thinning is not a common listed side effect of GLP-1 receptor agonists, but rapid weight loss from any cause—including GLP-1 therapy—can trigger telogen effluvium, a temporary shedding phase lasting several months. Nutritional deficiencies (iron, protein, zinc, vitamin D) during aggressive calorie reduction may worsen hair health. If shedding is severe or patchy, see a dermatologist to rule out other causes such as thyroid disease or alopecia areata.

Question 27

Is GLP-1 safe if I have thyroid nodules?

Accepted Answer

Thyroid nodules alone are not an automatic contraindication if you lack personal or family history of medullary thyroid carcinoma or MEN2. GLP-1 carries a precaution based on rodent studies, not proven human thyroid cancer risk in typical patients. Your endocrinologist may monitor nodules with ultrasound and review fine-needle aspiration results before prescribing. Report new neck lumps, hoarseness, or swallowing difficulty promptly.

Question 28

Can I take GLP-1 after a kidney transplant?

Accepted Answer

This requires specialist nephrology and transplant team approval. GLP-1 receptor agonists may offer metabolic benefits, but immunosuppressant interactions, fluctuating kidney function, and infection risk during GI side effects need individual assessment. Dose adjustments and closer monitoring of creatinine, drug levels, and hydration apply. Do not start GLP-1 after transplant without explicit clearance from your transplant physician.

Question 29

Can GLP-1 help fatty liver (NAFLD) in India?

Accepted Answer

Clinical trials show GLP-1 receptor agonists can reduce liver fat and improve NAFLD-related markers alongside weight loss—relevant given India's high NAFLD prevalence with metabolic syndrome. GLP-1 is not a standalone liver treatment; lifestyle modification remains foundational. Severe liver disease may need hepatology input before prescribing. Monitor alcohol intake and metabolic comorbidities concurrently.

Question 30

What blood tests are needed before starting GLP-1?

Accepted Answer

Typical baseline workup includes fasting glucose or HbA1c, kidney function (creatinine, eGFR), liver enzymes, lipid profile, thyroid function if clinically indicated, and pregnancy test when relevant. Your doctor may check calcitonin or review thyroid imaging history for MEN2/MTC screening. Repeat labs during titration monitor tolerance and metabolic response. Bring prior reports to your first consultation to avoid duplicate testing.

Question 31

What should I eat on GLP-1 therapy in India?

Accepted Answer

Prioritise smaller portions with adequate protein—dal, paneer, eggs, fish, soya—and plenty of vegetables and fibre. Use the half-plate vegetable model with quarter protein and quarter complex carbs (millet, brown rice). Avoid heavy fried foods during titration when nausea is common. Hydrate well. GLP-1 reduces appetite but does not replace balanced Indian nutrition or muscle-preserving protein intake.

Question 32

Can vegetarians use GLP-1 safely?

Accepted Answer

Yes. GLP-1 medicines are synthetic peptides, not animal-derived food products. Vegetarian and Jain patients need deliberate protein planning—dal, paneer, soya, curd—to prevent muscle loss during weight reduction. Monitor vitamin B12 and vitamin D.

Question 33

Can I drink alcohol on GLP-1?

Accepted Answer

Alcohol worsens nausea, adds empty calories, and increases hypoglycaemia risk if combined with sulfonylureas or insulin. Patients with fatty liver should minimise alcohol. If drinking, do so sparingly with food, avoid during titration peaks, and never on an empty stomach if on diabetes medicines.

Question 34

How do I travel with GLP-1 pens in India?

Accepted Answer

Carry prescription copies, keep pens in insulated cold bags before first use, and never check baggage with temperature extremes. Plan weekly injection timing across time zones with your doctor. Carry a sharps container for used needles. Identify licensed pharmacies at your destination for emergency refills.

Question 35

Will I regain weight if I stop GLP-1?

Accepted Answer

Substantial regain is common within a year of stopping without sustained lifestyle support or maintenance pharmacotherapy. Plan maintenance from treatment start—habits, exercise, and possibly continued lower-dose therapy. Discuss tapering with your doctor; do not stop diabetes medicines abruptly without glucose monitoring.

Question 36

Can I take GLP-1 with Ayurvedic or herbal supplements?

Accepted Answer

Tell your doctor about all supplements—many Ayurvedic preparations contain herbs that affect blood sugar, blood pressure, or liver enzymes. There is no established safety data for combining GLP-1 with specific traditional formulations. Avoid unverified "weight-loss" herbal products marketed alongside GLP-1 on social media. Prioritise evidence-based nutrition; do not replace prescribed medicines with supplements.

Question 37

How much exercise is safe on GLP-1 therapy?

Accepted Answer

Regular activity supports muscle preservation during weight loss—aim for 150 minutes weekly of moderate aerobic exercise plus twice-weekly resistance training as tolerated. Start gently during early titration when nausea is common. Hydrate well, especially in Indian heat. If on insulin or sulfonylureas, monitor for hypoglycaemia during longer workouts. Your physiotherapist or doctor can tailor intensity to your fitness level.

Question 38

Semaglutide vs tirzepatide—which is better?

Accepted Answer

Semaglutide activates GLP-1 receptors only; tirzepatide activates both GIP and GLP-1. Trials suggest tirzepatide may achieve greater average weight and HbA1c reductions at studied doses, but it costs more in India and individual tolerance varies. Oral semaglutide suits injection-averse patients. Your doctor selects based on clinical profile, cost, and prior tolerance—not social media trends.

Question 39

Can GLP-1 be taken with metformin?

Accepted Answer

Yes—this is a common and recommended combination when metformin alone is insufficient. Metformin usually continues unless kidney function or side effects prohibit it. GI symptoms from both may overlap initially; titration pacing helps.

Question 40

What happens to my other diabetes tablets on GLP-1?

Accepted Answer

Sulfonylureas are often reduced or stopped to prevent hypoglycaemia. SGLT2 inhibitors may continue for cardiorenal benefit alongside GLP-1. Insulin doses typically decrease when GLP-1 is added. DPP-4 inhibitors are usually stopped rather than combined. Never adjust doses yourself—work with your diabetologist.

Question 41

GLP-1 vs bariatric surgery—how do I choose?

Accepted Answer

GLP-1 suits moderate obesity with typical loss of 10–15% body weight at ongoing monthly cost. Surgery achieves greater sustained loss for severe obesity (often BMI ≥37.5 or ≥32.5 with major comorbidities) at ₹2–5 lakh upfront. Some patients trial GLP-1 before surgery; others use GLP-1 after surgery if weight recurs. Multidisciplinary assessment guides choice.

Question 42

Does Kesho prescribe or sell GLP-1?

Accepted Answer

No. Kesho is an education platform only. We help you understand GLP-1 drug classes, prepare doctor questions, and navigate nutrition and lifestyle. We do not diagnose, prescribe, sell pharmaceutical products, or determine eligibility. Always consult a qualified physician for medical decisions.

Question 43

Oral vs injectable semaglutide—which should I choose in India?

Accepted Answer

Both are CDSCO-approved semaglutide formulations with similar drug-class efficacy in trials, though injectable weekly pens may achieve slightly greater average weight reduction at studied doses. Oral semaglutide suits injection-averse patients but requires daily dosing on an empty stomach with strict timing rules—challenging during Indian fasting festivals or irregular meal patterns. Monthly costs are often comparable. Your doctor weighs convenience, tolerance, and adherence—not social media preference.

Question 44

Is liraglutide still prescribed in India?

Accepted Answer

Yes. Liraglutide—a once-daily injectable GLP-1 receptor agonist—remains available and prescribed for type 2 diabetes and weight management in India, often at lower monthly cost than newer weekly agents. It requires daily injections versus weekly semaglutide or dulaglutide. Efficacy and side-effect profiles differ by molecule; your diabetologist selects based on clinical need, insurance, and prior tolerance.

Question 45

Can GLP-1 be used with blood pressure medicines?

Accepted Answer

Yes. GLP-1 receptor agonists are commonly combined with antihypertensives and may modestly lower blood pressure through weight loss. Monitor for dizziness or lightheadedness during early titration, especially if already on multiple BP medicines. ACE inhibitors and ARBs often continue alongside GLP-1 for cardiorenal benefit in diabetes. Never stop BP medicines without medical advice.

Question 46

Is GLP-1 recommended for type 2 diabetes with heart disease?

Accepted Answer

GLP-1 receptor agonists with proven cardiovascular benefit in trials—such as liraglutide, semaglutide, and dulaglutide—are often preferred add-ons when type 2 diabetes coexists with established cardiovascular disease, alongside statins and blood pressure control per RSSDI/ICMR-aligned practice. Tirzepatide cardiovascular outcome data continues to evolve. Individualise with your cardiologist and diabetologist.

Question 47

How do I use a GLP-1 injection pen?

Accepted Answer

Always follow your doctor's and product leaflet instructions—steps vary slightly by device. General steps: wash hands; attach a new sterile needle; prime the pen per leaflet; select the prescribed dose; inject subcutaneously into abdomen, thigh, or upper arm; rotate injection sites weekly; dispose of needles in a sharps container. Never share pens. Ask your pharmacist or diabetes educator for a demonstration at first prescription.

Question 48

How often do I need to inject GLP-1?

Accepted Answer

Frequency depends on the molecule: semaglutide and dulaglutide are typically once weekly; liraglutide is once daily; tirzepatide is once weekly. Oral semaglutide is taken daily instead of injecting. Doses start low and increase gradually over weeks per titration schedules—do not skip ahead. Set phone reminders and align injection day with a consistent weekly routine.

Question 49

How should I store GLP-1 pens in Indian summer heat?

Accepted Answer

Unopened pens need refrigeration at 2–8°C—use a dedicated fridge compartment, not the freezer. After first use, most products tolerate room temperature up to 30°C for several weeks; avoid direct sunlight, car dashboards, and kitchen heat near stoves. During power cuts or travel, use insulated cold bags with ice packs—not loose ice touching the pen. Discard if exposed to extreme heat or if solution looks cloudy or discoloured.

Question 50

What should I do if I miss a GLP-1 dose?

Accepted Answer

Missed-dose rules vary by product—check your leaflet or call your doctor. For weekly injectables: if within a few days of the scheduled dose, inject as soon as remembered; if near the next dose, skip the missed one and resume your regular schedule—do not double dose. For daily liraglutide, take when remembered unless close to the next dose. Keep a dose diary or app reminder to maintain steady drug levels.

Question 51

How should I dispose of used GLP-1 pens in India?

Accepted Answer

Used injectable pens and needles are biomedical waste. Do not throw them in household dustbins. Many metro hospitals and pharmacies accept sharps in puncture-proof containers; some municipalities run biomedical waste collection. Never recap needles. If no local programme exists, store used pens in a sealed rigid container and ask your clinic or chemist about disposal options. CDSCO pharmacovigilance does not replace proper sharps disposal—protect waste handlers and the environment.

Question 52

Can GLP-1 affect mood, anxiety, or depression?

Accepted Answer

Large trials have not shown a consistent increase in depression or suicidal ideation with GLP-1 receptor agonists, but individual responses vary. Rapid weight change, nausea, and social stress can affect mood. If you notice persistent low mood, anxiety, or sleep changes after starting therapy, tell your doctor promptly—do not stop medicines abruptly without guidance. GLP-1 is not a mental health treatment; psychiatric support remains important when needed.

Question 53

How do I verify a GLP-1 product is CDSCO-approved?

Accepted Answer

Check the CDSCO approved drug database or SUGAM portal for the manufacturer, molecule, and formulation. Legitimate packs show batch number, expiry, storage instructions, and a licensed manufacturer address. Buy only from pharmacies with a valid prescription—avoid social-media sellers and unlabelled imports. If price seems impossibly low or packaging lacks Hindi/English inserts, treat it as a red flag and consult your doctor before use.

Question 54

When should I stop GLP-1 before surgery?

Accepted Answer

GLP-1 receptor agonists slow stomach emptying, raising aspiration risk under anaesthesia. Major surgical society guidance often recommends holding weekly GLP-1 injections for about one week before elective surgery with general anaesthesia or deep sedation—longer for daily agents or higher doses. Inform your surgeon and anaesthetist about GLP-1 use at pre-operative assessment. Do not stop diabetes medicines without a perioperative glucose plan.

Question 55

Can teenagers or children use GLP-1 in India?

Accepted Answer

Paediatric approvals are limited and indication-specific. Some GLP-1 receptor agonists are approved abroad for adolescents with obesity above defined age and BMI thresholds; Indian prescribing for minors requires paediatric endocrinology supervision and careful growth, bone health, and psychological assessment. GLP-1 is not appropriate for casual childhood weight management. Family-based lifestyle intervention remains first-line.

Question 56

How do I safely stop GLP-1 therapy?

Accepted Answer

Do not stop diabetes medicines abruptly without a plan—blood sugar may rise. For obesity-only use, discuss tapering versus stopping with your doctor, recognising regain risk. Semaglutide's long half-life means effects fade gradually over weeks. Maintain nutrition, protein intake, and exercise habits built during therapy. Schedule follow-up labs and weight checks at three and six months after stopping.

ପ୍ରଶ୍ନୋତ୍ତର

ମୌଳିକ ବିଷୟ ଏବଂ GLP-1 କିପରି କାମ କରେ

ଯୋଗ୍ୟତା ଏବଂ ଭାରତୀୟ ନିର୍ଦ୍ଦେଶାବଳୀ |

ମୂଲ୍ୟ, ପ୍ରବେଶ ଏବଂ ବୀମା |

ସୁରକ୍ଷା ଏବଂ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟା |

ପୁଷ୍ଟିକର, ଜୀବନଶ yle ଳୀ ଏବଂ ଦ Daily ନନ୍ଦିନ ଜୀବନ |

ତୁଳନା ଏବଂ ଅନ୍ୟାନ୍ୟ ic ଷଧ |

GLP-1 ic ଷଧ ବ୍ୟବହାର: କଲମ, ମାତ୍ରା ଏବଂ ସଂରକ୍ଷଣ |

ଅସ୍ତ୍ରୋପଚାର, ସ୍ Sit ତନ୍ତ୍ର ପରିସ୍ଥିତି ଏବଂ ଚିକିତ୍ସା ବନ୍ଦ କରିବା |